<DOC>
	<DOCNO>NCT02933034</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerance new intravenous diagnostic agent , SeeMore EVP 1001-1 , patient Cardiovascular Disease . The initial phase study , NCT01989195 enrol total 6 patient , close . This second phase add 10 patient safety cohort 60 additional patient total 70 patient .</brief_summary>
	<brief_title>Clinical Trial Manganese-Enhanced MRI ( MEMRI ) Assess Peri-Infarct Injury</brief_title>
	<detailed_description>This open-label , baseline-controlled study conduct . Adult male nonpregnant female patient refer evaluation dilate cardiomyopathy , ischemic cardiomyopathy , non-ischemic cardiomyopathy , atrial arrthymia also patient receive stem cell therapy relate ischemic dilate cardiomyopathy ( different trial ) recruit . An initial cohort study 6 patient conduct safety evaluation conduct proceed 60 additional patient . In initial cohort , patient dose base Phase 1 2 clinical trial data evaluation complete Eagle Vision Pharmaceutical , Inc . Subjects exclude receive investigational device within 30 day prior administration EVP1001-1 ; history drug abuse alcoholism ; take digitalis preparation ; history torsades ; NYHA Grade IV heart failure ; abnormal liver function test history liver disease ; uncontrolled hypertension ; abnormal calcium , potassium hemoglobin value baseline ; develop cardiac arrhythmia prior either exercise test -- EVP1001-1 administer . The parameter apply new group subject . Prior entry study , subject sign Informed Consent undergo physical examination include medical history , detail regard cardiac history , prescription over-the-counter drug questionnaire , vital sign , electrocardiogram ( ECG ) , evaluation major organ system , hematology , serum chemistry , urinalysis . In addition , female subject undergo serum pregnancy test . Starting 30 minute cardiac MRI scan ( CMR ) , subject take 16 mg tablet ondansetron mouth . CMR image subsequently take place EVP1001-1 administer approximately 15 minute scan contrast enhance image . EVP1001-1 administer intravenously approximately one minute . The subject receive 0.28 mL/kg EVP 1001-1 . All subject monitor closely ondansetron administration discharge image center . Following MEMRI , delayed-enhanced MRI ( DEMRI ) perform use 0.2mmol/kg . We compare two different contrast enhance image ( EVP1001-1 v Gadolinium ) determine viable , peri-infarct , intra-infarct myocardial tissue</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Manganese</mesh_term>
	<criteria>All subject enter must : least 18 year age . female , nonpregnant evidence serum pregnancy test use medicallyapproved method birth control , postmenopausal surgically sterile provide write informed consent receive oral write information study stable health base medical history , examination test positive pregnancy test ( female ) receive investigational drug device within 30 day prior administration SeeMore known hypersensitivity ondansetron selective serotonin 5HT3 receptor blocker history drug abuse alcoholism take digitalis preparation calcium channel blocker history torsades prolong QT/QTc interval NYHA Grade IV heart failure abnormal liver function test history liver disease uncontrolled hypertension ( Systolic Blood Pressure &gt; 140 Diastolic BP &gt; 90 consistently baseline ) abnormal baseline potassium calcium value hemoglobin less 10 g/dl noncompliant otherwise unlikely perform require protocol pretest likelihood CAD requisite number subject enter develop arrhythmia prior either exercise test ; SeeMore administer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ISCHEMIC OR CORONARY HEART DISEASE</keyword>
	<keyword>MYOCARDIAL INFARCTION</keyword>
	<keyword>MAGNETIC RESONANCE IMAGING</keyword>
	<keyword>DELAYED GADOLINIUM ENHANCEMENT MRI</keyword>
	<keyword>MANGANESE-ENHANCED MRI</keyword>
	<keyword>INFARCT VOLUME/SIZE</keyword>
	<keyword>ALL CAUSE MORTALITY</keyword>
	<keyword>VENTRICULAR ARRHYTHMIAS</keyword>
</DOC>